查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1675444

2025 年至 2033 年免疫疗法药物市场报告（按药物类型、治疗领域、最终用户和地区）

Immunotherapy Drugs Market Report by Drug Type, Therapy Area, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球免疫疗法药物市场规模达到 2,295 亿美元。人口老化导致不同类型的癌症盛行率不断上升、个人化医疗需求不断增加以及人们对早期发现和治疗的认识不断提高是推动市场发展的主要因素。

免疫治疗药物是一种旨在利用或改变免疫系统来对抗或控制疾病的医疗治疗方法。它们专注于特定的细胞和蛋白质，并有助于最大限度地减少对健康组织的伤害。与其他治疗方法相比，它们降低了产生抗药性的可能性，提供了更好的治疗效果，并且副作用更少。它们用于治疗各种类型的癌症，包括黑色素瘤、肺癌和乳腺癌。它们也用于控制特定的过敏反应和治疗类风湿性关节炎、狼疮和多发性硬化症等疾病。除此之外，由于免疫疗法药物能有效控制慢性发炎疾病，全球对免疫疗法药物的需求正在增加。

全球製药业的兴起和药局的扩张提供了良好的市场前景。此外，生物技术公司、製药公司和研究机构之间的策略合作和併购（M&A）正在支持免疫疗法产品的研究、开发和商业化活动。此外，人工智慧（AI）和巨量资料分析在研发活动中的整合正在提高效率和精确度。这种技术整合使得快速识别目标、优化临床试验和预测患者反应成为可能。

免疫治疗药物市场趋势/驱动因素：

目标疾病的盛行率不断上升

由于生活方式的改变和不健康的饮食习惯，各种癌症的发生率不断上升，这催化了对免疫疗法等创新有效治疗方法的需求不断增长。此外，早期发现和个人化治疗方案的需求正在鼓励患者和医疗保健提供者采用这些先进的治疗方案。除此之外，快速的城市化和有害车辆排放导致的污染水平上升导致各种慢性疾病，这为免疫疗法治疗创造了新的机会。此外，老年人口不断增加，使人们极易患上肿瘤、癌症和其他健康疾病，这也推动了对有效治疗和技术的需求，例如免疫疗法药物。

采用个人化医疗

个人化医疗在各个医疗领域的应用日益广泛，以促进以患者为中心的医疗服务，对市场产生了积极影响。此外，次世代定序和生物标记分析等先进诊断工具的开发使得能够精确识别需要特定免疫疗法的患者。诊断技术的这些进步有利于早期干预并允许个性化的治疗计划，从而有助于提高免疫疗法的整体效果。除此之外，个人化的免疫疗法减少了反覆试验的可能性。此外，这种有针对性的方法最大限度地减少了无效治疗的使用，避免了不必要的副作用，促进了更快的恢復，并降低了医疗成本，从而促进了市场成长。

政府和监管支持

各国政府和监管机构持续关注免疫疗法药物和疗法的研发，市场前景看好。此外，他们也为开发新型免疫疗法和优化现有免疫疗法所需的深入研究提供资金支持。除此之外，政府、研究机构和私人企业之间的合作也支持了市场的成长。这些合作促进了知识交流并加速了跨国突破性免疫疗法的发展。此外，政府推出的多项支持性医疗政策也鼓励了免疫疗法的采用和报销。

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第五章：全球免疫治疗药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 单株抗体
  • 疫苗
  • 干扰素 Alpha 和 β
  • 白血球介素

第 7 章：市场区隔：依治疗领域

  • 癌症
  • 自体免疫和发炎疾病
  • 传染病
  • 其他的

第 8 章：市场区隔：依最终用户

  • 医院
  • 诊所
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112025A6639

The global immunotherapy drugs market size reached USD 229.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 449.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.36% during 2025-2033. The growing prevalence of different cancer types due to the aging population, rising demand for personalized medicines, and the increasing awareness among individuals about early detection and treatment are some of the major factors propelling the market.

Immunotherapy drugs are medical treatments designed to utilize or modify the immune system to fight or control diseases. They focus on specific cells and proteins and aid in minimizing harm to healthy tissues. They reduce the likelihood of developing resistance, offer better outcomes, and have fewer side effects as compared to other treatments. They are utilized in treating various types of cancers, including melanoma, lung, and breast cancer. They are also used in managing specific allergic reactions and treating diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Besides this, as they are effective in controlling chronic inflammatory diseases, the demand for immunotherapy drugs is increasing across the globe.

The rise in the pharmaceutical industry and the expansion of pharmacies worldwide is offering a favorable market outlook. Moreover, strategic collaborations and mergers and acquisitions (M&A) between biotech firms, pharmaceutical companies, and research institutions are supporting the research, development, and commercialization activities of immunotherapy products. Furthermore, the integration of artificial intelligence (AI) and big data analytics in research and development (R&D) activities is enhancing efficiency and precision. This technological integration is enabling the rapid identification of targets, optimization of clinical trials, and prediction of patient responses.

Immunotherapy Drugs Market Trends/Drivers:

The increasing prevalence of target diseases

The rising occurrence of different types of cancer due to lifestyle changes and unhealthy dietary patterns is catalyzing the demand for innovative and effective treatments like immunotherapy is growing. Additionally, the early detection and need for personalized therapy options are encouraging patients and healthcare providers to adopt these advanced treatment alternatives. Apart from this, rapid urbanization and rising pollution levels due to harmful vehicular emissions are resulting in various chronic diseases, which is creating new opportunities for immunotherapy treatments. Furthermore, the increasing aging population, which is highly susceptible to tumor, cancer, and other health conditions, is driving the need for effective treatments and technologies, like immunotherapy drugs.

Adoption of personalized medicines

The increasing utilization of personalized medicines in various medical fields to promote a more patient-centered approach is positively influencing the market. Additionally, the development of advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, is enabling the precise identification of patients for specific immunotherapies. These advancements in diagnostics facilitate early intervention and allow for personalized treatment plans, which aid in enhancing the overall effectiveness of immunotherapy. Apart from this, personalized immunotherapies reduce the likelihood of trial-and-error approaches. Furthermore, this targeted approach minimizes the use of ineffective treatments, avoids unnecessary side effects, facilitates quicker recoveries, and reduces healthcare costs, which is contributing to market growth.

Governmental and regulatory support

Governments and regulatory bodies of various countries are continuously focusing on the development of immunotherapy drugs and therapies, which is offering a favorable market outlook. Additionally, they are providing financial support for conducting the in-depth studies required to develop novel immunotherapies and optimize existing ones. Apart from this, partnerships between governments, research institutions, and private companies are supporting market growth. These collaborations facilitate knowledge exchange and accelerate the development of groundbreaking immunotherapy treatments across borders. Furthermore, the introduction of several supportive governmental healthcare policies is encouraging the adoption and reimbursement of immunotherapies.

Immunotherapy Drugs Industry Segmentation:

Breakup by Drug Type:

  • Monoclonal Antibodies
  • Vaccines
  • Interferons Alpha and Beta
  • Interleukins

Monoclonal antibodies represent the largest market segment

Breakup by Therapy Area:

  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases
  • Others

Cancer accounts for the majority of the market share

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals hold the majority of the market share

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest immunotherapy drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share as the region has a well-established healthcare infrastructure that allows for the efficient distribution and utilization of immunotherapy drugs. Sophisticated medical facilities and well-trained healthcare professionals facilitate the widespread adoption of these treatments. Additionally, the region witnesses substantial investments from public and private sectors in healthcare and biotechnology, which facilitates research, drug development, and commercialization of immunotherapy products. Apart from this, the regulatory bodies in North America, such as the Food and Drug Administration (FDA), offer a conducive environment for drug approval. Furthermore, strategic collaborations between academia, biotech firms, and pharmaceutical companies ensure a dynamic environment for continuous innovation and growth in the field of immunotherapy.

Competitive Landscape:

Companies are actively engaged in various activities to stay competitive and innovate. They are conducting extensive research and development (R&D) activities, working on discovering new targets and optimizing existing therapies. Additionally, these companies are forming strategic partnerships with academic institutions, leveraging their expertise to fuel innovation. Apart from this, they are investing in cutting-edge manufacturing technologies to produce immunotherapy drugs efficiently and at scale. Furthermore, regulatory teams within these companies are collaborating with governmental bodies to ensure compliance with emerging rules and gain expedited approvals for novel treatment. Moreover, many companies are actively participating in international conferences and symposia, sharing knowledge, and learning from global peers.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • GSK plc
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.

Key Questions Answered in This Report

  • 1.How big is the global immunotherapy drugs market?
  • 2.What is the expected growth rate of the global immunotherapy drugs market during 2025-2033?
  • 3.What are the key factors driving the global immunotherapy drugs market?
  • 4.What has been the impact of COVID-19 on the global immunotherapy drugs market?
  • 5.What is the breakup of the global immunotherapy drugs market based on the drug type?
  • 6.What is the breakup of the global immunotherapy drugs market based on the therapy area?
  • 7.What is the breakup of the global immunotherapy drugs market based on the end user?
  • 8.What are the key regions in the global immunotherapy drugs market?
  • 9.Who are the key players/companies in the global immunotherapy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunotherapy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Interferons Alpha and Beta
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Interleukins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune and Inflammatory Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim International GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Immunotherapy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Immunotherapy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Immunotherapy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Immunotherapy Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Immunotherapy Drugs Market: Breakup by Therapy Area (in %), 2024
  • Figure 6: Global: Immunotherapy Drugs Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Immunotherapy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Immunotherapy Drugs (Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Immunotherapy Drugs (Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Immunotherapy Drugs (Interleukins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Immunotherapy Drugs (Interleukins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Immunotherapy Drugs (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Immunotherapy Drugs (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Immunotherapy Drugs (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Immunotherapy Drugs (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Immunotherapy Drugs (Other Therapy Areas) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Immunotherapy Drugs (Other Therapy Areas) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Immunotherapy Drugs (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Immunotherapy Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Immunotherapy Drugs (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Immunotherapy Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Immunotherapy Drugs (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Immunotherapy Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Immunotherapy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Immunotherapy Drugs Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Immunotherapy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Immunotherapy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Immunotherapy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunotherapy Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Immunotherapy Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Immunotherapy Drugs Market Forecast: Breakup by Therapy Area (in Million USD), 2025-2033
  • Table 4: Global: Immunotherapy Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Immunotherapy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Immunotherapy Drugs Market: Competitive Structure
  • Table 7: Global: Immunotherapy Drugs Market: Key Players